Sanofi gets binding bids for consumer unit
Ventyx Biosciences, Sanofi
Banks and other lenders are readying over €10B ($11.1B) in funding as New York-based buyout firm Clayton Dubilier & Rice and ...
Sanofi named a new chief scientific officer this week, part of a series of moves aimed at redefining the company.
After a few years in biotech, Mike Quigley, Ph.D., is returning to the pharma fold, taking up the top science spot at Sanofi.
NEW YORK (Reuters) - Sanofi Chief Executive Paul Hudson said on Monday that the company has not made a final decision yet on ...
23h
Analyst Eric Le Berrigaud from Stifel Nicolaus maintained a Buy rating on Sanofi (SNYNF – Research Report) and increased the price target ...
The Sanofi equity investment means the Big Pharma will receive exclusive rights of first negotiation surrounding VTX3232, an ...
EADV: New data reinforce Sanofi’s innovative approach and leadership across immune-mediated skin diseases 24 abstracts for Dupixent, including 4 oral presentations, highlight impact of ...
The U.S. Food and Drug Administration said on Friday it has approved the use of a drug combination along with Sanofi's ...
The FDA approved Sanofi's Sarclisa (isatuximab) in combination with VRd as a first-line treatment for newly diagnosed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback